-
Information-Publications
-
Identification of calcium and integrin-binding protein 1 as a reprogrammed glucose metabolism mediator to restrict immune cell infiltration in the stromal …Details
-
Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axisDetails
-
Combination of a Novel Fusion Protein CD3εζ28 and Bispecific T Cell Engager Enhances the Persistance and Anti-Cancer Effects of T CellsDetails
-
Arisaema heterophyllum blume monomer stigmasterol targets PPARγ and inhibits the viability and tumorigenicity of lung adenocarcinoma cells NCI-H1975Details
-
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancerDetails
-
YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathwayDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands